{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T23:04:29Z","timestamp":1787871869136,"version":"build-2784847793"},"reference-count":29,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"4","license":[{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-sa\/4.0"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2024,10]]},"abstract":"<jats:sec>\n                    <jats:title>Objective:<\/jats:title>\n                    <jats:p>In severe cases, COVID-19 can lead to a hyperinflammatory state, resulting in devastating outcomes. Immune modulation using steroids or other immune modulators can regulate the intensity of the inflammatory response; however, this theory has not been adequately assessed in practice. The current study aims to investigate the use of corticosteroids alone or in combination with tocilizumab to treat patients with severe COVID-19.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>\n                      This cross-sectional study was conducted on 166 Iranian patients with severe COVID-19 infection at Al-Zahra Hospital, who were treated with the standard treatment for severe COVID-19 infection, as per the 11\n                      <jats:sup>th<\/jats:sup>\n                      version of the Iranian guideline for COVID-19 treatment. Patients were categorized into three treatment groups based on the dose of corticosteroid treatment and tocilizumab therapy: (a) high-dose methylprednisolone (&gt;1 mg\/kg) alone, (b) low-dose methylprednisolone (&lt;1 mg\/kg) followed by one dose of tocilizumab (8 mg\/kg); and (c) high-dose methylprednisolone (&gt;1 mg\/kg) followed by one dose of tocilizumab (8 mg\/kg). Mortality of patients as our primary outcome, laboratory parameters, length of hospitalization, intensive care unit (ICU) admission requirement, and drug-related adverse events were compared between groups.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Findings:<\/jats:title>\n                    <jats:p>The second group showed significantly better outcomes, including shorter ICU stays, lower C-reactive protein and lactate dehydrogenase levels, and higher oxygen saturation and platelet counts than the other groups. Logistic regression revealed increased risks of mortality, nosocomial infection, and adverse effects, including hepatic and renal dysfunction and gastrointestinal bleeding, in Groups B and C compared with Group A.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion:<\/jats:title>\n                    <jats:p>In all evaluated parameters, a low-dose steroid followed by tocilizumab was superior to a high-dose steroid alone or combined with tocilizumab. Although this combination treatment has been assessed worldwide, few studies have focused on its application in Iranian patients with severe COVID-19.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.4103\/jrpp.jrpp_2_25","type":"journal-article","created":{"date-parts":[[2025,4,24]],"date-time":"2025-04-24T05:00:10Z","timestamp":1745470810000},"page":"111-118","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":2,"title":["Use of Immune Modulating Agents to Regulate Hyperinflammation in Severe COVID 19: Assessment of Tocilizumab Use in Combination with Steroids"],"prefix":"10.4103","volume":"13","author":[{"given":"Somayeh","family":"Sadeghi","sequence":"first","affiliation":[{"name":"Immunodeficiency Diseases Research Center, Isfahan University of Medical Sciences, Isfahan, Iran"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zohre","family":"Naderi","sequence":"additional","affiliation":[{"name":"Department of Pulmonary and Critical Care, Isfahan University of Medical Sciences, Isfahan, Iran"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nima","family":"Arezoomandi","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Isfahan University of Medical Sciences, Isfahan, Iran"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mozhdeh","family":"Saghaei","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Isfahan University of Medical Sciences, Isfahan, Iran"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fereshteh","family":"Tavakoli","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Isfahan University of Medical Sciences, Isfahan, Iran"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mahsa","family":"Hajizadeh","sequence":"additional","affiliation":[{"name":"Department of Pulmonary and Critical Care, Johns Hopkins University, Baltimore, Maryland, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2025,4,24]]},"reference":[{"key":"R1-20260423","doi-asserted-by":"crossref","first-page":"31957","DOI":"10.34172\/jrip.2022.31957","article-title":"On admission hemoglobin and albumin, as the two novel factors associated with thrombosis in COVID-19 pneumonia","volume":"11","author":"Sadeghi","year":"2022","journal-title":"J Renal Inj Prev"},{"key":"R2-20260423","doi-asserted-by":"crossref","first-page":"136","DOI":"10.4103\/jrpp.jrpp_42_22","article-title":"Efficacy and safety comparison of two different doses of dexamethasone in hospitalized patients with COVID-19: A randomized clinical trial","volume":"11","author":"Sadeghi","year":"2022","journal-title":"J Res Pharm Pract"},{"key":"R3-20260423","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1016\/S0140-6736(20)30211-7","article-title":"Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: A descriptive study","volume":"395","author":"Chen","year":"2020","journal-title":"Lancet"},{"key":"R4-20260423","doi-asserted-by":"crossref","first-page":"91","DOI":"10.5045\/br.2023.2022201","article-title":"Efficacy of plasmapheresis in neutropenic patients suffering from cytokine storm because of severe COVID-19 infection","volume":"58","author":"Sadeghi","year":"2023","journal-title":"Blood Res"},{"key":"R5-20260423","first-page":"4","article-title":"A rapid advice guideline for the diagnosis and treatment of 2019 novel coronavirus (2019-nCoV) infected pneumonia (standard version)","volume":"7","author":"Jin","year":"2020","journal-title":"Mil Med Res"},{"key":"R6-20260423","doi-asserted-by":"crossref","first-page":"10970","DOI":"10.1073\/pnas.2005615117","article-title":"Effective treatment of severe COVID-19 patients with tocilizumab","volume":"117","author":"Xu","year":"2020","journal-title":"Proc Natl Acad Sci U S A"},{"key":"R7-20260423","doi-asserted-by":"crossref","first-page":"934","DOI":"10.1001\/jamainternmed.2020.0994","article-title":"Risk factors associated with acute respiratory distress syndrome and death in patients with coronavirus disease 2019 pneumonia in Wuhan, China","volume":"180","author":"Wu","year":"2020","journal-title":"JAMA Intern Med"},{"key":"R8-20260423","doi-asserted-by":"crossref","first-page":"e250","DOI":"10.1093\/cid\/ciac724","article-title":"Infectious Diseases Society of America guidelines on the treatment and management of patients with coronavirus disease 2019 (COVID-19)","volume":"78","author":"Bhimraj","year":"2024","journal-title":"Clin Infect Dis"},{"key":"R9-20260423","first-page":"9","article-title":"Clinical Management of Severe Acute Respiratory Infection (SARI) when COVID-19 Disease is Suspected: Interim Guidance","volume":"16","year":"2020","journal-title":"Paediatrics and Family Medicine"},{"key":"R10-20260423","doi-asserted-by":"crossref","first-page":"e12","DOI":"10.34172\/ijdrc.2023.e12","article-title":"The effect of short-term methylprednisolone on clinical outcome and lung CT scan in severe COVID-19: In-hospital and six weeks later follow-up","volume":"1","author":"Mirenayat","year":"2023","journal-title":"Int J Drug Res Clin"},{"key":"R11-20260423","article-title":"Higher dose corticosteroids in hospitalised COVID-19 patients requiring ventilatory support (RECOVERY): a randomised, controlled, open-label, platform trial","year":"2022","journal-title":"medRxiv"},{"key":"R12-20260423","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.1001\/jama.2020.17022","article-title":"Effect of hydrocortisone on mortality and organ support in patients with severe COVID-19: The REMAP-CAP COVID-19 corticosteroid domain randomized clinical trial","volume":"324","author":"Angus","year":"2020","journal-title":"JAMA"},{"key":"R13-20260423","doi-asserted-by":"crossref","first-page":"1307","DOI":"10.1001\/jama.2020.17021","article-title":"Effect of Dexamethasone on Days Alive and Ventilator-Free in Patients With Moderate or Severe Acute Respiratory Distress Syndrome and COVID-19: The CoDEX randomized clinical trial","volume":"324","author":"Sirio-Libanes","year":"2020","journal-title":"JAMA"},{"key":"R14-20260423","doi-asserted-by":"crossref","first-page":"e0237831","DOI":"10.1371\/journal.pone.0237831","article-title":"Tocilizumab and steroid treatment in patients with COVID-19 pneumonia","volume":"15","author":"Mikulska","year":"2020","journal-title":"Plos One"},{"key":"R15-20260423","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1080\/23744235.2021.1884286","article-title":"Corticosteroids and tocilizumab reduce in-hospital mortality in severe COVID-19 pneumonia: A retrospective study in a Spanish hospital","volume":"53","author":"Van den Eynde","year":"2021","journal-title":"Infect Dis (Lond)"},{"key":"R16-20260423","doi-asserted-by":"crossref","first-page":"2333","DOI":"10.1056\/NEJMoa2028836","article-title":"Efficacy of tocilizumab in patients hospitalized with COVID-19","volume":"383","author":"Stone","year":"2020","journal-title":"N Engl J Med"},{"key":"R17-20260423","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1016\/j.medcli.2020.07.001","article-title":"Tocilizumab plus glucocorticoids in severe and critically COVID-19 patients. A single center experience","volume":"155","author":"Jim\u00e9nez-Br\u00edtez","year":"2020","journal-title":"Med Clin (Barc)"},{"key":"R18-20260423","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1001\/jamainternmed.2020.6615","article-title":"Effect of tocilizumab versus standard care on clinical worsening in patients hospitalized with COVID-19 pneumonia: A randomized clinical trial","volume":"181","author":"Salvarani","year":"2021","journal-title":"JAMA Intern Med"},{"key":"R19-20260423","doi-asserted-by":"crossref","first-page":"7","DOI":"10.21037\/jeccm-20-92","article-title":"Severity of illness scores at presentation predict ICU admission and mortality in COVID-19","volume":"5","author":"Wilfong","year":"2021","journal-title":"J Emerg Crit Care Med"},{"key":"R20-20260423","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1016\/j.mayocp.2020.10.022","article-title":"Clinical characteristics, treatment, and outcomes of critically ill patients with COVID-19: A scoping review","volume":"96","author":"Huang","year":"2021","journal-title":"Mayo Clin Proc"},{"key":"R21-20260423","doi-asserted-by":"crossref","first-page":"551889","DOI":"10.3389\/fpubh.2020.551889","article-title":"Iran\u2019s approach to COVID-19: Evolving treatment protocols and ongoing clinical trials","volume":"8","author":"Rahmanzade","year":"2020","journal-title":"Front Public Health"},{"key":"R22-20260423","doi-asserted-by":"crossref","first-page":"e0252057","DOI":"10.1371\/journal.pone.0252057","article-title":"Dexamethasone versus methylprednisolone high dose for COVID-19 pneumonia","volume":"16","author":"Pinz\u00f3n","year":"2021","journal-title":"PLoS One"},{"key":"R23-20260423","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1007\/s40199-021-00430-8","article-title":"Comparing the efficacy of tocilizumab with corticosteroid therapy in treating COVID-19 patients: A systematic review and meta-analysis","volume":"30","author":"Lim","year":"2022","journal-title":"Daru"},{"key":"R24-20260423","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1001\/jamainternmed.2020.6252","article-title":"Association between early treatment with tocilizumab and mortality among critically ill patients with COVID-19","volume":"181","author":"Gupta","year":"2021","journal-title":"JAMA Intern Med"},{"key":"R25-20260423","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1001\/jamainternmed.2020.6820","article-title":"Effect of tocilizumab versus usual care in adults hospitalized with COVID-19 and moderate or severe pneumonia: A randomized clinical trial","volume":"181","author":"Hermine","year":"2021","journal-title":"JAMA Intern Med"},{"key":"R26-20260423","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1007\/s40121-020-00373-8","article-title":"Combination of tocilizumab and steroids to improve mortality in patients with severe COVID-19 infection: A Spanish, multicenter, cohort study","volume":"10","author":"Ruiz-Antor\u00e1n","year":"2021","journal-title":"Infect Dis Ther"},{"key":"R27-20260423","doi-asserted-by":"crossref","first-page":"101362","DOI":"10.1016\/j.eclinm.2022.101362","article-title":"Tocilizumab plus dexamethasone versus dexamethasone in patients with moderate-to-severe COVID-19 pneumonia: A randomised clinical trial from the CORIMUNO-19 study group","volume":"46","author":"Hermine","year":"2022","journal-title":"EClinicalMedicine"},{"key":"R28-20260423","doi-asserted-by":"crossref","first-page":"1297","DOI":"10.1093\/cid\/ciaa829","article-title":"High-dose but not low-dose corticosteroids potentially delay viral shedding of patients with COVID-19","volume":"72","author":"Li","year":"2021","journal-title":"Clin Infect Dis"},{"key":"R29-20260423","doi-asserted-by":"crossref","first-page":"e373","DOI":"10.1093\/cid\/ciaa1177","article-title":"Methylprednisolone as adjunctive therapy for patients hospitalized with coronavirus disease 2019 (COVID-19; METCOVID): A randomized, double-blind, phase IIb, placebo-controlled trial","volume":"72","author":"Jeronimo","year":"2021","journal-title":"Clin Infect Dis"}],"container-title":["Journal of Research in Pharmacy Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.4103\/jrpp.jrpp_2_25","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,13]],"date-time":"2026-08-13T19:00:19Z","timestamp":1786647619000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.4103\/jrpp.jrpp_2_25"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10]]},"references-count":29,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2024]]}},"URL":"https:\/\/doi.org\/10.4103\/jrpp.jrpp_2_25","relation":{},"ISSN":["2319-9644","2279-042X"],"issn-type":[{"value":"2319-9644","type":"print"},{"value":"2279-042X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,10]]},"assertion":[{"value":"2024-05-21","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-08-14","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}